Therapeutic Delivery – Multimedia
eBook
Development of Better LNP-Based Genetic Medicines
Lipid nanoparticles (LNPs) are effective non-viral vectors, which are widely used delivery vehicles for genetic medicines. It is therefore important to understand and limit LNP-related impurities to help ensure genetic product integrity and mitigate risks to patient safety and product efficacy.
App Note / Case Study
Distinguishing Oxidative Impurities From Ionizable Lipids Used in LNP Formulations
Lipid nanoparticles (LNPs), comprised of ionizable lipids, are used to deliver oligonucleotides to work as therapeutics or to stimulate the immune system, as in the initial mRNA-based COVID vaccines.
How To Guide
Analytical Solutions for mRNA Vaccines and Therapeutics
Messenger RNA (mRNA) therapy enables the body to make the proteins needed to prevent, treat or cure diseases but, unlike traditional biologics, mRNAs are large and delicate molecules that need to be protected by lipid nanoparticles (LNPs) on the journey to reach target cells.
Video
Why Vaccine Developers Need a Charged Aerosol Detector (CAD)
Watch this short presentation to learn how a high resolution HPLC-CAD platform can provide accurate and fast characterization of your LNP formulations.
Video
How To Ensure Lipid Nanoparticle (LNP) Quality With Adam Crowe
In this episode of Teach Me in 10 we are joined by Adam Crowe, manager of analytical development at Precision NanoSystems Inc.
App Note / Case Study
Distinguishing Oxidative Impurities From Ionizable Lipids Using Electron Activated Dissociation
Lipid nanoparticles (LNPs) comprised of ionizable lipids can be used to deliver oligonucleotides to work as therapeutics or to stimulate the immune system. Detailed and sensitive characterization of the ionizable lipid and its related impurities is necessary to ensure quality, however, obtaining the level of detail needed is challenging with current LC-MS-based methodologies.
Video
Targeting RNA Therapeutics to the Lung: Ten Years On.
Speaking at the Advances in Drug Discovery & Development 2022 online symposium, Sterghios Moschos delivered his talk on targeted RNA therapeutics in the lung.
App Note / Case Study
Gene Modification for Cell Therapy Applications
The clinical success of CAR T-cell therapy has spurred increased interest and investments in the advanced therapeutics industry.
App Note / Case Study
Analysis of Lipid Nanoparticle Composition
In recent years, interest in lipid nanoparticle (LNP) research has increased due to promising opportunities for RNA-based therapy and gene-editing technology, and LNPs are showing promise as nucleic acid delivery vehicles in the pharmaceutical industry.
Listicle
Recent Advances in Gene Therapy
Download this listicle to explore recent advances in gene therapy such as novel virus-free delivery systems, precision targeting using lipid nanoparticles and safer gene editing systems.
Advertisement
